The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
KontRASt-02: A phase III trial investigating the efficacy and safety of the KRASG12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C-mutated NSCLC.
 
Federico Cappuzzo
Honoraria - Amgen; AstraZeneca/MedImmune; Bayer; bristol-myers; Lilly; MSD Oncology; Novocure; Pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Lilly; MSD Oncology; Novocure; pfizer; PharmaMar; Roche/Genentech; Sanofi; Takeda
Travel, Accommodations, Expenses - OSE Immunotherapeutics
 
Gilberto Castro
Honoraria - Amgen; AstraZeneca; Bristol-Myers Squibb; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Libbs; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Sanofi; Takeda; Yuhan
Speakers' Bureau - Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche; Takeda
Travel, Accommodations, Expenses - AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Serono; Merck Sharp & Dohme; Novartis; Pfizer; Roche
 
Jin-Hyoung Kang
Honoraria - AstraZeneca; Boehringer Ingelheim; Lilly O.; Ono Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Genexine; MSD Oncology; Ono Pharmaceutical; Yuhan
Speakers' Bureau - Boehringer Ingelheim; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical; Yuhan
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)
 
Odd Terje Brustugun
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD Oncology; Novartis; Pfizer; Sanofi/Regeneron
Consulting or Advisory Role - Bayer Health (Inst); MSD Oncology (Inst); Roche (Inst); Takeda (Inst)
Research Funding - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
 
Parneet Kaur Cheema
Honoraria - Amgen; AstraZeneca; GlaxoSmithKline; Janssen Oncology; Merck
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; Bristol Myers Squibb; Janssen Oncology; Merck; Novartis; Novartis; Pfizer; Roche
 
Taofeek K. Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; Coherus Biosciences; GenCart; Taobob LLC
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; BeiGene; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Coherus Biosciences; Daichi; Eisai; Eisai; EMD Serono; Exelixis; G1 Therapeutics; Ipsen; Janssen; Jazz Pharmaceuticals; Lilly; MedImmune; Merck; Novartis; PharmaMar; Roche/Genentech; Takeda; Triptych Health Partners; Wells Fargo; Xcovery; Xcovery; Zentalis
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Corvus Pharmaceuticals; Eisai (Inst); Fujifilm (Inst); G1 Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Loxo/Lilly (Inst); Merck (Inst); Mersana (Inst); Meryx Pharmaceuticals (Inst); Novartis (Inst); Oncorus (Inst); Pfizer (Inst); Regeneron (Inst); Roche/Genentech (Inst); Turning Point Therapeutics (Inst); United Therapeutics (Inst); WindMIL (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Novartis; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Anne-Sophie Longin
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Research Funding - Novartis
 
Aislyn Boran
Employment - Daiichi Sankyo; Novartis
Stock and Other Ownership Interests - Daiichi Sankyo; Novartis; TetraLogic Pharmaceuticals
Travel, Accommodations, Expenses - Novartis
 
Jiawei Duan
Employment - Novartis; Novartis (I)
Stock and Other Ownership Interests - Novartis; Novartis (I)
 
Rafael Caparica
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Herbert H. F. Loong
Consulting or Advisory Role - Boehringer Ingelheim; Celgene; Eisai; GlaxoSmithKline; Guardant Health; Illumina; Lilly; Novartis; Roche/Genentech; Takeda
Speakers' Bureau - Bayer; Guardant Health; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche